A Systematic Review of SARS-CoV-2-Associated Hepatic Dysfunction and the Impact on the Clinical Outcome of COVID-19.
coronavirus disease 2019
covid-19
liver
liver failure
liver function tests
liver injury
sars-cov-2
transaminases
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
03
06
2022
accepted:
14
07
2022
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
18
8
2022
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) has rapidly spread across the globe since December 2019. The spectrum of clinical manifestations of COVID-19 ranges from mild to life-threatening forms. Alteration of hepatic function in COVID-19 is multifactorial. The objective of this systematic review is to assess the relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced hepatic dysfunction and the clinical outcome in patients infected with COVID-19. We methodically explored several electronic databases (PubMed, PubMed Central, MEDLINE, and Google Scholar) in April 2022 using focused words and terms of medical subject headings for appropriate studies. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for conducting our systematic review. Hepatic dysfunction was identified as elevation of liver function tests (LFTs) above the upper limit of normal. The clinical outcome was described as a combination of mortality, intensive care unit (ICU) transfer, and the need for mechanical ventilation (MV). The initial search yielded a total of 7187 studies. After elimination of duplicates, exclusion of studies based on irrelevant titles and abstracts, comprehensive analysis of full-text formats, and evaluation of quality, a total of 16 studies were eligible to be included in our systematic review. In the 16 selected studies, there were 23,962 patients. The SARS-CoV-2 virus can negatively affect several organ systems by interacting with specific receptors widely expressed in the human body. A multifactorial etiology of hepatic dysfunction is observed in COVID-19. SARS-CoV-2 infection is associated with abnormal LFTs. Significantly higher mortality, ICU admissions, and requirement for MV are associated with LFT alterations. For this reason, patients infected with COVID-19 must have their hepatic function closely monitored.
Identifiants
pubmed: 35974857
doi: 10.7759/cureus.26852
pmc: PMC9375135
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e26852Informations de copyright
Copyright © 2022, Radivojevic et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Ann Hepatol. 2020 Nov - Dec;19(6):592-596
pubmed: 32858226
Ann Hepatol. 2021 Dec;26:100553
pubmed: 34624543
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Hepatology. 2020 Jul;72(1):287-304
pubmed: 32298473
SN Compr Clin Med. 2021;3(2):419-436
pubmed: 33521564
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e313-e319
pubmed: 33653988
J Clin Med. 2021 Sep 17;10(18):
pubmed: 34575333
J Clin Virol. 2020 Jun;127:104357
pubmed: 32305884
Can J Gastroenterol Hepatol. 2021 Oct 5;2021:1622533
pubmed: 34621710
World J Clin Cases. 2021 Jun 6;9(16):3814-3825
pubmed: 34141738
Hepatol Int. 2021 Apr;15(2):493-501
pubmed: 33534084
Eur J Intern Med. 2020 Jul;77:18-24
pubmed: 32507608
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Intern Emerg Med. 2021 Jun;16(4):815-830
pubmed: 33453010
Liver Int. 2020 Oct;40(10):2394-2406
pubmed: 32526083
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Gastroenterology. 2020 Sep;159(3):1137-1140.e2
pubmed: 32389667
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Aliment Pharmacol Ther. 2020 Sep;52(6):1051-1059
pubmed: 32697870
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Dig Dis Sci. 2022 Aug;67(8):4204-4214
pubmed: 34487314
Ann Hepatol. 2021 Mar-Apr;21:100298
pubmed: 33359234
Ann Hepatol. 2020 Nov - Dec;19(6):614-621
pubmed: 32920162
J Family Med Prim Care. 2021 Sep;10(9):3252-3256
pubmed: 34760739
Scand J Clin Lab Invest. 2020 Oct;80(6):441-447
pubmed: 32449374
Biomedicines. 2020 Sep 04;8(9):
pubmed: 32899640
Pathogens. 2020 Mar 20;9(3):
pubmed: 32245083
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101556
pubmed: 33139241
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e320-e328
pubmed: 33560687
Hepatol Int. 2020 Sep;14(5):723-732
pubmed: 33026573
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560